Abstract: The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the disclosure includes methods of inhibiting histone acetylation in a cell, comprising contacting the cell with a chromane compound of the disclosure. Additional embodiments include methods of treating a disease capable of treatment by inhibition of histone acetylation in a patient in need thereof, comprising administering a chromane compound of the disclosure.

Abstract: Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient having a neurodegenerative disease, traumatic brain injury, acute kidney disease, liver injury, ischemia/reperfusion injury, ischemic stroke, intracerebral hemorrhage, liver fibrosis, diabetes, acute myeloid leukemia, age-related macular degeneration, psoriasis, a hemolytic disorder, or an inflammatory disease.